Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
Aims/hypothesis The bone-related peptide osteoprotegerin is produced by vascular cells and is involved in the process of vascular calcification. The aim of this study was to investigate the predictive value of plasma levels of osteoprotegerin in relation to mortality, cardiovascular events and deter...
Gespeichert in:
| Veröffentlicht in: | Diabetologia 2008-11, Vol.51 (11), p.2100-2107 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2107 |
|---|---|
| container_issue | 11 |
| container_start_page | 2100 |
| container_title | Diabetologia |
| container_volume | 51 |
| creator | Jorsal, A. Tarnow, L. Flyvbjerg, A. Parving, H.-H. Rossing, P. Rasmussen, L. M. |
| description | Aims/hypothesis
The bone-related peptide osteoprotegerin is produced by vascular cells and is involved in the process of vascular calcification. The aim of this study was to investigate the predictive value of plasma levels of osteoprotegerin in relation to mortality, cardiovascular events and deterioration in kidney function in patients with type 1 diabetes.
Methods
This prospective observational follow-up study included 397 type 1 diabetic patients with overt diabetic nephropathy (243 men; age [mean±SD] 42.1 ± 10.6 years, duration of diabetes 28.3 ± 9.9 years, GFR 67 ± 28 ml min
−1
1.73 m
2
) and a group of 176 patients with longstanding type 1 diabetes and persistent normoalbuminuria (105 men; age 42.6 ± 9.7 years, duration of diabetes 27.6 ± 8.3 years).
Results
The median (range) follow-up period was 11.3 (0.0–12.9) years. Among patients with diabetic nephropathy, individuals with high osteoprotegerin levels (fourth quartile) had significantly higher all-cause mortality than patients with low levels (first quartile) (covariate-adjusted hazard ratio [HR] 3.00 [1.24–7.27]). High osteoprotegerin levels also predicted cardiovascular mortality (covariate-adjusted HR 4.88 [1.57–15.14]). Furthermore, patients with high osteoprotegerin levels had significantly higher risk of progression to end-stage renal disease than patients with low levels (covariate-adjusted HR 4.32 [1.45–12.87]). In addition, patients with high levels of plasma osteoprotegerin had an elevated rate of decline in GFR.
Conclusions/interpretation
High levels of osteoprotegerin predict all-cause and cardiovascular mortality in patients with diabetic nephropathy. Furthermore, high levels of osteoprotegerin predict deterioration of kidney function towards end-stage renal disease. |
| doi_str_mv | 10.1007/s00125-008-1123-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69640310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1569601141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-fe9b586ea78d6573b1b7d8347a90dad7829034ddc1549a85ab6faa99c7e56c903</originalsourceid><addsrcrecordid>eNp1kcuKFTEQhoMozpnRB3AjQXB2rbn0Jb2UwRsM6ELBXVOdVHsy5iRtkh7pl_FZTc85OCC4ClR99aeoj5BnnL3ijHWvE2NcNBVjquJcyEo9IDteS1GxWqiHZLe1K67ab2fkPKUbxphs6vYxOeOq471SYkd-f3aQDkBDyhjmGDJ-x2g9dXiLLtE5orE6Uw3R2HALSS8OIgVvKDhXaVgS0kOIGZzN613dYC4JIUK2wdMw0R_WeFzptHh9VyrpeZ2RcmosjJitpnOB0edEf9m8px7nfQyltl-fkEcTuIRPT-8F-fru7ZerD9X1p_cfr95cV7quRa4m7MdGtQidMm3TyZGPnVGy7qBnBkynRM9kbYzmTd2DamBsJ4C-1x02rS69C3J5zC0n-LlgysPBJo3OgcewpKHt25pJvoEv_gFvwhJ92W0QXKq6ZVwWiB8hHUNKEadhjvYAcR04GzZzw9HcUMwNm7lBlZnnp-BlPKC5nzipKsDLE1AsgJsieG3TX06wjZNbkDhyqbR8sXm_4f9__wOV-bSC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213846013</pqid></control><display><type>article</type><title>Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Jorsal, A. ; Tarnow, L. ; Flyvbjerg, A. ; Parving, H.-H. ; Rossing, P. ; Rasmussen, L. M.</creator><creatorcontrib>Jorsal, A. ; Tarnow, L. ; Flyvbjerg, A. ; Parving, H.-H. ; Rossing, P. ; Rasmussen, L. M.</creatorcontrib><description>Aims/hypothesis
The bone-related peptide osteoprotegerin is produced by vascular cells and is involved in the process of vascular calcification. The aim of this study was to investigate the predictive value of plasma levels of osteoprotegerin in relation to mortality, cardiovascular events and deterioration in kidney function in patients with type 1 diabetes.
Methods
This prospective observational follow-up study included 397 type 1 diabetic patients with overt diabetic nephropathy (243 men; age [mean±SD] 42.1 ± 10.6 years, duration of diabetes 28.3 ± 9.9 years, GFR 67 ± 28 ml min
−1
1.73 m
2
) and a group of 176 patients with longstanding type 1 diabetes and persistent normoalbuminuria (105 men; age 42.6 ± 9.7 years, duration of diabetes 27.6 ± 8.3 years).
Results
The median (range) follow-up period was 11.3 (0.0–12.9) years. Among patients with diabetic nephropathy, individuals with high osteoprotegerin levels (fourth quartile) had significantly higher all-cause mortality than patients with low levels (first quartile) (covariate-adjusted hazard ratio [HR] 3.00 [1.24–7.27]). High osteoprotegerin levels also predicted cardiovascular mortality (covariate-adjusted HR 4.88 [1.57–15.14]). Furthermore, patients with high osteoprotegerin levels had significantly higher risk of progression to end-stage renal disease than patients with low levels (covariate-adjusted HR 4.32 [1.45–12.87]). In addition, patients with high levels of plasma osteoprotegerin had an elevated rate of decline in GFR.
Conclusions/interpretation
High levels of osteoprotegerin predict all-cause and cardiovascular mortality in patients with diabetic nephropathy. Furthermore, high levels of osteoprotegerin predict deterioration of kidney function towards end-stage renal disease.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-008-1123-8</identifier><identifier>PMID: 18719882</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Associated diseases and complications ; Biological and medical sciences ; Biomarkers - blood ; Calcification ; Cardiovascular disease ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - mortality ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - epidemiology ; Diabetic Angiopathies - mortality ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - epidemiology ; Diabetic Nephropathies - mortality ; Diabetic nephropathy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinology ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Glycated Hemoglobin A - metabolism ; Human Physiology ; Humans ; Internal Medicine ; Kidney diseases ; Kidney Failure, Chronic - epidemiology ; Kidney Failure, Chronic - mortality ; Kidneys ; Laboratories ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Mortality ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Osteoprotegerin - blood ; Peptides ; Plasma ; Predictive Value of Tests ; Renal failure ; Survival Analysis ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Diabetologia, 2008-11, Vol.51 (11), p.2100-2107</ispartof><rights>Springer-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-fe9b586ea78d6573b1b7d8347a90dad7829034ddc1549a85ab6faa99c7e56c903</citedby><cites>FETCH-LOGICAL-c442t-fe9b586ea78d6573b1b7d8347a90dad7829034ddc1549a85ab6faa99c7e56c903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00125-008-1123-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00125-008-1123-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20719838$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18719882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jorsal, A.</creatorcontrib><creatorcontrib>Tarnow, L.</creatorcontrib><creatorcontrib>Flyvbjerg, A.</creatorcontrib><creatorcontrib>Parving, H.-H.</creatorcontrib><creatorcontrib>Rossing, P.</creatorcontrib><creatorcontrib>Rasmussen, L. M.</creatorcontrib><title>Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><addtitle>Diabetologia</addtitle><description>Aims/hypothesis
The bone-related peptide osteoprotegerin is produced by vascular cells and is involved in the process of vascular calcification. The aim of this study was to investigate the predictive value of plasma levels of osteoprotegerin in relation to mortality, cardiovascular events and deterioration in kidney function in patients with type 1 diabetes.
Methods
This prospective observational follow-up study included 397 type 1 diabetic patients with overt diabetic nephropathy (243 men; age [mean±SD] 42.1 ± 10.6 years, duration of diabetes 28.3 ± 9.9 years, GFR 67 ± 28 ml min
−1
1.73 m
2
) and a group of 176 patients with longstanding type 1 diabetes and persistent normoalbuminuria (105 men; age 42.6 ± 9.7 years, duration of diabetes 27.6 ± 8.3 years).
Results
The median (range) follow-up period was 11.3 (0.0–12.9) years. Among patients with diabetic nephropathy, individuals with high osteoprotegerin levels (fourth quartile) had significantly higher all-cause mortality than patients with low levels (first quartile) (covariate-adjusted hazard ratio [HR] 3.00 [1.24–7.27]). High osteoprotegerin levels also predicted cardiovascular mortality (covariate-adjusted HR 4.88 [1.57–15.14]). Furthermore, patients with high osteoprotegerin levels had significantly higher risk of progression to end-stage renal disease than patients with low levels (covariate-adjusted HR 4.32 [1.45–12.87]). In addition, patients with high levels of plasma osteoprotegerin had an elevated rate of decline in GFR.
Conclusions/interpretation
High levels of osteoprotegerin predict all-cause and cardiovascular mortality in patients with diabetic nephropathy. Furthermore, high levels of osteoprotegerin predict deterioration of kidney function towards end-stage renal disease.</description><subject>Adult</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Calcification</subject><subject>Cardiovascular disease</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - mortality</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - epidemiology</subject><subject>Diabetic Angiopathies - mortality</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - epidemiology</subject><subject>Diabetic Nephropathies - mortality</subject><subject>Diabetic nephropathy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinology</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Human Physiology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - epidemiology</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Kidneys</subject><subject>Laboratories</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Osteoprotegerin - blood</subject><subject>Peptides</subject><subject>Plasma</subject><subject>Predictive Value of Tests</subject><subject>Renal failure</subject><subject>Survival Analysis</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kcuKFTEQhoMozpnRB3AjQXB2rbn0Jb2UwRsM6ELBXVOdVHsy5iRtkh7pl_FZTc85OCC4ClR99aeoj5BnnL3ijHWvE2NcNBVjquJcyEo9IDteS1GxWqiHZLe1K67ab2fkPKUbxphs6vYxOeOq471SYkd-f3aQDkBDyhjmGDJ-x2g9dXiLLtE5orE6Uw3R2HALSS8OIgVvKDhXaVgS0kOIGZzN613dYC4JIUK2wdMw0R_WeFzptHh9VyrpeZ2RcmosjJitpnOB0edEf9m8px7nfQyltl-fkEcTuIRPT-8F-fru7ZerD9X1p_cfr95cV7quRa4m7MdGtQidMm3TyZGPnVGy7qBnBkynRM9kbYzmTd2DamBsJ4C-1x02rS69C3J5zC0n-LlgysPBJo3OgcewpKHt25pJvoEv_gFvwhJ92W0QXKq6ZVwWiB8hHUNKEadhjvYAcR04GzZzw9HcUMwNm7lBlZnnp-BlPKC5nzipKsDLE1AsgJsieG3TX06wjZNbkDhyqbR8sXm_4f9__wOV-bSC</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Jorsal, A.</creator><creator>Tarnow, L.</creator><creator>Flyvbjerg, A.</creator><creator>Parving, H.-H.</creator><creator>Rossing, P.</creator><creator>Rasmussen, L. M.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy</title><author>Jorsal, A. ; Tarnow, L. ; Flyvbjerg, A. ; Parving, H.-H. ; Rossing, P. ; Rasmussen, L. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-fe9b586ea78d6573b1b7d8347a90dad7829034ddc1549a85ab6faa99c7e56c903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Calcification</topic><topic>Cardiovascular disease</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - mortality</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - epidemiology</topic><topic>Diabetic Angiopathies - mortality</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - epidemiology</topic><topic>Diabetic Nephropathies - mortality</topic><topic>Diabetic nephropathy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinology</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Human Physiology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - epidemiology</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Kidneys</topic><topic>Laboratories</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Osteoprotegerin - blood</topic><topic>Peptides</topic><topic>Plasma</topic><topic>Predictive Value of Tests</topic><topic>Renal failure</topic><topic>Survival Analysis</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jorsal, A.</creatorcontrib><creatorcontrib>Tarnow, L.</creatorcontrib><creatorcontrib>Flyvbjerg, A.</creatorcontrib><creatorcontrib>Parving, H.-H.</creatorcontrib><creatorcontrib>Rossing, P.</creatorcontrib><creatorcontrib>Rasmussen, L. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jorsal, A.</au><au>Tarnow, L.</au><au>Flyvbjerg, A.</au><au>Parving, H.-H.</au><au>Rossing, P.</au><au>Rasmussen, L. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy</atitle><jtitle>Diabetologia</jtitle><stitle>Diabetologia</stitle><addtitle>Diabetologia</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>51</volume><issue>11</issue><spage>2100</spage><epage>2107</epage><pages>2100-2107</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Aims/hypothesis
The bone-related peptide osteoprotegerin is produced by vascular cells and is involved in the process of vascular calcification. The aim of this study was to investigate the predictive value of plasma levels of osteoprotegerin in relation to mortality, cardiovascular events and deterioration in kidney function in patients with type 1 diabetes.
Methods
This prospective observational follow-up study included 397 type 1 diabetic patients with overt diabetic nephropathy (243 men; age [mean±SD] 42.1 ± 10.6 years, duration of diabetes 28.3 ± 9.9 years, GFR 67 ± 28 ml min
−1
1.73 m
2
) and a group of 176 patients with longstanding type 1 diabetes and persistent normoalbuminuria (105 men; age 42.6 ± 9.7 years, duration of diabetes 27.6 ± 8.3 years).
Results
The median (range) follow-up period was 11.3 (0.0–12.9) years. Among patients with diabetic nephropathy, individuals with high osteoprotegerin levels (fourth quartile) had significantly higher all-cause mortality than patients with low levels (first quartile) (covariate-adjusted hazard ratio [HR] 3.00 [1.24–7.27]). High osteoprotegerin levels also predicted cardiovascular mortality (covariate-adjusted HR 4.88 [1.57–15.14]). Furthermore, patients with high osteoprotegerin levels had significantly higher risk of progression to end-stage renal disease than patients with low levels (covariate-adjusted HR 4.32 [1.45–12.87]). In addition, patients with high levels of plasma osteoprotegerin had an elevated rate of decline in GFR.
Conclusions/interpretation
High levels of osteoprotegerin predict all-cause and cardiovascular mortality in patients with diabetic nephropathy. Furthermore, high levels of osteoprotegerin predict deterioration of kidney function towards end-stage renal disease.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18719882</pmid><doi>10.1007/s00125-008-1123-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-186X |
| ispartof | Diabetologia, 2008-11, Vol.51 (11), p.2100-2107 |
| issn | 0012-186X 1432-0428 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69640310 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Associated diseases and complications Biological and medical sciences Biomarkers - blood Calcification Cardiovascular disease Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - mortality Diabetes. Impaired glucose tolerance Diabetic Angiopathies - blood Diabetic Angiopathies - epidemiology Diabetic Angiopathies - mortality Diabetic Nephropathies - blood Diabetic Nephropathies - epidemiology Diabetic Nephropathies - mortality Diabetic nephropathy Endocrine pancreas. Apud cells (diseases) Endocrinology Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glycated Hemoglobin A - metabolism Human Physiology Humans Internal Medicine Kidney diseases Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - mortality Kidneys Laboratories Male Medical sciences Medicine Medicine & Public Health Metabolic Diseases Middle Aged Mortality Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Osteoprotegerin - blood Peptides Plasma Predictive Value of Tests Renal failure Survival Analysis Urinary system involvement in other diseases. Miscellaneous |
| title | Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A29%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20osteoprotegerin%20levels%20predict%20cardiovascular%20and%20all-cause%20mortality%20and%20deterioration%20of%20kidney%20function%20in%20type%201%20diabetic%20patients%20with%20nephropathy&rft.jtitle=Diabetologia&rft.au=Jorsal,%20A.&rft.date=2008-11-01&rft.volume=51&rft.issue=11&rft.spage=2100&rft.epage=2107&rft.pages=2100-2107&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-008-1123-8&rft_dat=%3Cproquest_cross%3E1569601141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213846013&rft_id=info:pmid/18719882&rfr_iscdi=true |